BG107745A - Инхибиране на зависимостта на туморни клетки от растежния фактор - Google Patents

Инхибиране на зависимостта на туморни клетки от растежния фактор Download PDF

Info

Publication number
BG107745A
BG107745A BG107745A BG10774503A BG107745A BG 107745 A BG107745 A BG 107745A BG 107745 A BG107745 A BG 107745A BG 10774503 A BG10774503 A BG 10774503A BG 107745 A BG107745 A BG 107745A
Authority
BG
Bulgaria
Prior art keywords
use according
group
tumor cells
cells
egf
Prior art date
Application number
BG107745A
Other languages
Bulgarian (bg)
English (en)
Inventor
Rosemarie Lichtner
Ulrike Fuhrmann
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051609A external-priority patent/DE10051609A1/de
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of BG107745A publication Critical patent/BG107745A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG107745A 2000-10-18 2003-04-18 Инхибиране на зависимостта на туморни клетки от растежния фактор BG107745A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24101000P 2000-10-18 2000-10-18
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PCT/EP2001/012004 WO2002032429A2 (en) 2000-10-18 2001-10-17 Use of inhibitors of progesterone receptor for treating cancer

Publications (1)

Publication Number Publication Date
BG107745A true BG107745A (bg) 2004-01-30

Family

ID=26007397

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107745A BG107745A (bg) 2000-10-18 2003-04-18 Инхибиране на зависимостта на туморни клетки от растежния фактор

Country Status (26)

Country Link
EP (1) EP1414465B1 (hu)
JP (1) JP4335525B2 (hu)
KR (1) KR20030044006A (hu)
CN (1) CN1311833C (hu)
AT (1) ATE339208T1 (hu)
AU (2) AU1595802A (hu)
BG (1) BG107745A (hu)
BR (1) BR0114677A (hu)
CA (1) CA2423013A1 (hu)
CY (1) CY1106289T1 (hu)
CZ (1) CZ299945B6 (hu)
DE (1) DE60123138T2 (hu)
DK (1) DK1414465T3 (hu)
EA (1) EA005945B1 (hu)
EE (1) EE200300156A (hu)
ES (1) ES2272561T3 (hu)
HK (1) HK1071697A1 (hu)
HR (1) HRP20030386A2 (hu)
HU (1) HUP0301461A3 (hu)
IL (2) IL154974A0 (hu)
MX (1) MXPA03002953A (hu)
NO (1) NO20031745L (hu)
NZ (1) NZ545965A (hu)
PL (1) PL366415A1 (hu)
SK (1) SK4752003A3 (hu)
WO (1) WO2002032429A2 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
FR2789393B1 (fr) * 1999-02-05 2001-10-12 Centre Nat Rech Scient Lactol steroidique

Also Published As

Publication number Publication date
HUP0301461A3 (en) 2010-01-28
CZ299945B6 (cs) 2008-12-29
DK1414465T3 (da) 2007-01-29
EE200300156A (et) 2003-08-15
CA2423013A1 (en) 2002-04-25
WO2002032429A2 (en) 2002-04-25
IL154974A0 (en) 2003-10-31
PL366415A1 (en) 2005-01-24
BR0114677A (pt) 2003-10-07
DE60123138T2 (de) 2007-09-13
EA005945B1 (ru) 2005-08-25
IL154974A (en) 2007-05-15
CN1311833C (zh) 2007-04-25
EP1414465A2 (en) 2004-05-06
EA200300468A1 (ru) 2003-10-30
AU2002215958B2 (en) 2006-08-17
HK1071697A1 (en) 2005-07-29
NO20031745D0 (no) 2003-04-15
CN1551772A (zh) 2004-12-01
CY1106289T1 (el) 2011-10-12
EP1414465B1 (en) 2006-09-13
DE60123138D1 (de) 2006-10-26
AU2002215958C1 (en) 2002-04-29
JP4335525B2 (ja) 2009-09-30
ES2272561T3 (es) 2007-05-01
WO2002032429A3 (en) 2004-02-19
KR20030044006A (ko) 2003-06-02
MXPA03002953A (es) 2003-08-07
JP2004513094A (ja) 2004-04-30
NO20031745L (no) 2003-04-15
SK4752003A3 (en) 2003-10-07
HUP0301461A2 (hu) 2003-10-28
HRP20030386A2 (en) 2005-04-30
NZ545965A (en) 2007-09-28
AU1595802A (en) 2002-04-29
ATE339208T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
Leung et al. Non-genomic actions of the androgen receptor in prostate cancer
Simoncini et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells
Sutherland et al. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells
US5545634A (en) Activation of androgen receptors with low dose non-masculinizing androgenic compounds
Schwartz et al. Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women
Rugo The breast cancer continuum in hormone-receptor–positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
Christ et al. Cardiovascular steroid actions: swift swallows or sluggish snails?
BG107745A (bg) Инхибиране на зависимостта на туморни клетки от растежния фактор
US20040157811A1 (en) Inhibition of the growth factor dependency of tumor cells
AU2002215958A1 (en) Use of inhibitors of progesterone receptor for treating cancer
Kamaraju et al. Leveraging antiprogestins in the treatment of metastatic breast cancer
NO329949B1 (no) Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft
AU2001244372A1 (en) Use of fulvestrant in the treatment of resistant breast cancer
UA76128C2 (en) Use of progesterone receptor inhibitors for treating steroid-resistant breast cancer
PT94051B (pt) Processo para a preparacao de composicoes farmaceuticas compreendendo 17alfa-etinil-17beta-hidroxi-18-metil-4,15-estradieno-3-ona-(gestoden)
Ji Progesterone Receptor Membrane Component 1 Promotes Cell Proliferation and Tamoxifen Resistance through Alteration of Sexual Receptors in Breast Cancer
Cherian Novel tools to identify estrogen regulated genes important for breast and ovarian cancer cell proliferation
Banerjee The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer
Mamounas Antiaromatase agents after adjuvant tamoxifen: rationale and clinical implications
Friedl et al. The Role of Prolonged Antihormonal Treatment of Breast Cancer: A Strategy for Adjuvant Therapy
Kollara Androgen receptor associated-protein 70 (ARA70) expression in breast cancer, possible relationship with her2/neu overexpression
Davis et al. Program Information From the Division of Cancer Treatment, National Cancer Institute Page Inhibitors of L-Asparagine Synthetase, In Vitro 1493 David A. Cooney, John S. Driscoll, Harry A. Milman, HN Jayaram, and
Veronesi et al. New developments in breast cancer research